Cardinal Health (NYSE: CAH) to buy AdaptHealth’s Diabetes Health arm and Strive Medical for $360m

Cardinal Health, Inc. (NYSE: CAH) has entered into two separate definitive agreements to acquire the Diabetes Health business of AdaptHealth Corp. (NASDAQ: AHCO) for $235 million in cash and, in its entirety, urology-led home medical supply provider Strive Medical, for a combined approximate $360 million in cash, subject to working-capital adjustments. Both transactions are expected to close subject to customary conditions and regulatory approvals, and Cardinal Health, Inc. expects them to be accretive to non-GAAP earnings per share in the first 12 months after close. The Diabetes Health price sits against a business that generated $592 million of net revenue in 2025 but only $26 million of adjusted earnings before interest, taxes, depreciation and amortisation, a 57 percent year-on-year collapse in segment profitability that culminated in a $128 million non-cash goodwill impairment. The central question for both sides is not whether the strategic logic is sound, since it clearly extends the at-Home Solutions strategy that Cardinal Health, Inc. has been assembling under Chief Executive Officer Jason Hollar, but whether Cardinal Health, Inc.’s scale can restore Diabetes Health economics quickly enough to justify the price while AdaptHealth Corp. redeploys proceeds into its deleveraging and refocus toward sleep, respiratory and home medical equipment.

Why does AdaptHealth Corp.’s $235 million exit price look small relative to Diabetes Health’s $592 million revenue base?

The headline mismatch is stark. AdaptHealth Corp.’s Diabetes Health segment reported net revenue of $592.4 million for the year ended 31 December 2025, down from $614.4 million in 2024. Adjusted EBITDA over the same period fell to $26.1 million from $60.5 million, a 56.9 percent decline that pushed segment margin from 9.9 percent to 4.4 percent. AdaptHealth Corp. management attributed the deterioration to a payor-mix shift from commercial to government payors, movement of diabetes patients from durable medical equipment suppliers to dual-benefit and pharmacy-only channels, more insulin pumps being dispensed through pharmacy rather than distribution, manufacturers taking additional volume in-house and a decline in continuous glucose monitor patient census. The board also recorded a $128 million non-cash goodwill impairment charge related to the Diabetes Health segment’s fair value in the fourth quarter of 2025.

Against that operational reset, a $235 million cash headline for a business with more than 225,000 patients on service, direct-to-patient centralised mail-order infrastructure and a functioning continuous glucose monitor and insulin pump distribution capability implies roughly nine times trailing adjusted EBITDA on a segment whose earnings had already been marked down. If the underlying franchise can be stabilised, and if the payor-channel headwinds either abate or are met with a more competitive commercial construct under a new owner, the multiple looks materially lower on a forward basis. That is precisely the point Leerink Partners analyst Michael Cherny made in a same-day note, describing the deal as a logical strategic tuck-in while flagging that Diabetes Health would need operational improvements to restore growth and profitability, and noting that Cardinal Health, Inc.’s scale should help execute that turnaround. The value in this transaction sits inside the delta between where AdaptHealth Corp. is selling and what Cardinal Health, Inc. can operate.

What is Cardinal Health, Inc. actually buying, and how does it fit the at-Home Solutions build under Jason Hollar?

Cardinal Health, Inc. is buying a centralised, mail-order, direct-to-patient diabetes supplies platform serving more than 225,000 people annually across continuous glucose monitors and insulin pumps, plus Strive Medical, which serves more than 20,000 patients annually as a multi-specialty supplier focused on urology, wound care, ostomy and incontinence. Both slot directly into the at-Home Solutions growth pillar Cardinal Health, Inc. has been building since the $1.1 billion acquisition of Advanced Diabetes Supply Group, which closed in April 2025 and reshaped the at-Home Solutions patient base around a national diabetes network of roughly 500,000 patients.

Chief Executive Officer Jason Hollar framed today’s transactions as a natural extension of that strategy, referencing the ContinuCare Pathway diabetes supply-management programme and the Publix Super Markets Inc. partnership that Cardinal Health, Inc. has been layering on top of the Advanced Diabetes Supply Group base. The at-Home Solutions business generated a 34 percent revenue increase to $1.7 billion in the second quarter of fiscal 2026, with segment profit rising 52 percent to $179 million, showing that the ADS integration is delivering both scale and margin leverage. Adding a further 225,000 diabetes patients on service, most of them mail-order continuous glucose monitor and insulin pump users, deepens that platform without requiring a comparably large capital outlay.

How does the Diabetes Health segment’s 57 percent adjusted EBITDA collapse in 2025 shape the acquisition thesis?

The turnaround thesis is the transaction. Cardinal Health, Inc. is not paying full price for a stable earnings stream, it is paying a controlled price for a franchise that its target already impaired. Three specific levers should attract institutional attention. First, integration into the ADS platform should reduce duplicated corporate, information technology and distribution overhead, potentially recovering some of the fixed-cost absorption that fell away with the 2025 volume decline. Second, Cardinal Health, Inc.’s existing manufacturer relationships across continuous glucose monitors and insulin pumps, combined with its national medical distribution scale, should provide a stronger competitive position in the payor negotiations and channel-mix battles that have driven so much of the 2025 pressure. Third, the ContinuCare Pathway construct suggests a route to recapture some of the pharmacy-channel migration by offering pharmacy partners a more integrated supply model, which addresses one of the exact headwinds AdaptHealth Corp. cited in its 2025 segment commentary.

None of that is guaranteed. AdaptHealth Corp.’s explanations for the 2025 collapse point to structural shifts in the diabetes supply landscape, not to isolated operating missteps, and structural shifts do not always reverse in the hands of a larger buyer. But the acquisition price appears to be sized to reflect that risk rather than assume it away, and Cardinal Health, Inc.’s stated first-year accretion is defined against non-GAAP earnings per share rather than a specific segment margin outcome, giving management some flexibility on how the operational turn is delivered.

Where does Strive Medical fit alongside the Solaris Health platform inside The Specialty Alliance?

Strive Medical is the smaller of today’s two transactions in dollar terms, since the residual approximately $125 million of the combined $360 million outlay is implicit rather than disclosed, but strategically it is a meaningful complement. It broadens the enterprise-wide urology footprint that Cardinal Health, Inc. has been assembling around Solaris Health, the country’s leading urology multi-specialty MSO with more than 750 providers, which The Specialty Alliance acquired on 3 November 2025. Where Solaris Health delivers the physician-services channel into urology, Strive Medical delivers the direct-to-patient supplies channel serving conditions those same physicians treat, alongside adjacent categories in wound care, ostomy and incontinence. The result is a more integrated urology position that can capture value at both the clinical-services layer and the supplies layer of a single therapeutic corridor.

For Cardinal Health, Inc., the significance is that at-Home Solutions is not being built as a diabetes-only pillar. It is being built as a chronic-care distribution platform that covers multiple high-frequency, high-loyalty therapeutic categories, each with its own reimbursement mechanics and patient-engagement dynamics. Strive Medical, at just over 20,000 patients annually, is small on its own, but it slots into a wider architecture that already includes diabetes and gastroenterology-adjacent services through GI Alliance.

What does the timing tell investors about AdaptHealth Corp.’s deleveraging pivot toward sleep, respiratory and home medical equipment?

For AdaptHealth Corp., today’s disposal is consistent with a portfolio simplification that has been underway for several quarters. The company divested non-core assets during 2025, refinanced its capital structure in April 2026 with a $1.1 billion senior secured credit facility comprising a $325 million term loan A, a $325 million delayed-draw term loan and a $450 million revolver, and announced on 7 July 2026 that it would redeem its senior notes due 2028. Recent rating upgrades from S&P Global Ratings and Moody’s Ratings acknowledged an improved financial profile. Diabetes Health had accounted for 18.7 percent of AdaptHealth Corp.’s 2025 revenue but a far smaller and rapidly shrinking share of adjusted EBITDA, and the segment carried the $128 million goodwill impairment that dented full-year GAAP results.

Exiting Diabetes Health at $235 million cash removes an underperforming earnings stream, generates further balance-sheet capacity to accelerate debt reduction from the 2025 year-end net leverage ratio of 2.75 times, and lets management concentrate operating attention on Sleep Health, Respiratory Health and the Wellness at Home segments, plus the capitated contract onboarding that consumed significant infrastructure investment in 2025. The strategic story AdaptHealth Corp. is telling shareholders is one of a more focused home medical equipment specialist with lower leverage, and today’s transaction is a concrete data point supporting that narrative rather than a distress signal.

How does the combined $360 million outlay compare with the $1.1 billion Advanced Diabetes Supply Group deal from 2024?

Set against the $1.1 billion Advanced Diabetes Supply Group deal announced in November 2024 and closed in April 2025, today’s $360 million combined outlay looks small, but the comparison is instructive. Advanced Diabetes Supply Group brought roughly 500,000 diabetes patients, a platform position and the strategic foundation for at-Home Solutions. Today’s Diabetes Health transaction adds roughly 225,000 diabetes patients, or approximately 45 percent of the Advanced Diabetes Supply Group patient base, for around 21 percent of the price. The implicit patient-value comparison is not perfect, since the two businesses have different payor mixes, cost bases and growth profiles, but it indicates that Cardinal Health, Inc. is now consolidating diabetes distribution at meaningfully lower per-patient valuations than the platform deal set 20 months ago. That is exactly what a scaled roll-up should be able to achieve as it becomes the natural home for smaller distressed or non-core diabetes networks.

Strive Medical, meanwhile, is not being valued on the same lens. Its strategic value sits in the urology adjacency and the multi-specialty supplies capability rather than in per-patient economics, and the deal is not sized to move the needle for Cardinal Health, Inc.’s consolidated results on its own.

What regulatory, integration and payor risks could delay accretion or complicate the turnaround plan?

The transactions are subject to customary closing conditions and regulatory approvals, and no specific antitrust concerns have been flagged, but a few risks warrant attention. Payor-channel dynamics that hurt Diabetes Health in 2025 are not fully under Cardinal Health, Inc.’s control, and pharmacy-benefit-manager decisions on dual-benefit and pharmacy-only supplier arrangements can shift volume in ways that even a well-integrated distribution operator cannot immediately offset. Manufacturer decisions on in-house distribution, another 2025 headwind, will remain a variable regardless of ownership.

Integration risk is real but not extreme. Cardinal Health, Inc. is already 15 months into the Advanced Diabetes Supply Group integration, which management has said is running strongly, and the new patient base is directionally similar to what the platform already serves. That should compress the learning curve on the diabetes side. Strive Medical is a smaller organisation being folded into a much larger enterprise-wide medical distribution capability, and its execution risk sits in maintaining specialised urology customer relationships as the operating platform changes.

AdaptHealth Corp. also flagged that it was investigating a security incident on 2 July 2026. The company has not, based on public disclosures reviewed for this article, tied that matter directly to the Diabetes Health perimeter. Buyers of any healthcare technology-enabled distribution business will want representations and indemnities on cyber matters, and investors watching for Q2 2026 results should look for any follow-up disclosure on scope or financial impact.

How are Cardinal Health, Inc. and AdaptHealth Corp. shares positioned heading into Q4 fiscal 2026 results on 11 August?

Cardinal Health, Inc. shares traded around $237 in early July 2026, close to the 52-week high of $243.19 and well above the low of $137.75 set over the past year, giving a market capitalisation of roughly $55 billion on approximately 234 million shares outstanding. Sell-side sentiment has been building, with TD Cowen raising its price target to $275 from $255 on 9 July 2026 and Bank of America Securities raising its target to $260 from $240 on 2 July 2026, both maintaining Buy ratings. Cardinal Health, Inc. is scheduled to report fourth-quarter and full-year fiscal 2026 results on 11 August 2026, before the opening of trading, and today’s transactions are unlikely to be the primary catalyst on that call. Investors will be more focused on year-end at-Home Solutions revenue and profit trajectory, Advanced Diabetes Supply Group integration progress, capital-return guidance following $750 million of fiscal 2026 share repurchases already completed year-to-date through the second quarter, and any updated fiscal 2027 framing.

AdaptHealth Corp. shares closed at $10.59 on 15 July 2026, up 3.93 percent on the day, sitting between the 52-week low of $8.06 and the 52-week high of $13.43 with a market capitalisation of about $1.38 billion. Sell-side price targets recently include $15 at both Baird and RBC Capital and $14 at UBS Group, all above the current traded level. AdaptHealth Corp. reported first-quarter 2026 revenue of $819.8 million and, on 7 July 2026, announced the redemption of its senior notes due 2028. Today’s Diabetes Health disposal, combined with the April 2026 refinancing and the pending 2028 notes redemption, is precisely the sort of balance-sheet action the recent sell-side thesis has been leaning on to justify targets above the current share price. The next AdaptHealth Corp. quarterly report will be the more direct catalyst for how much of that thesis is being validated.

Key takeaways from the Cardinal Health and AdaptHealth Diabetes Health and Strive Medical transactions

• Cardinal Health, Inc. has agreed to buy AdaptHealth Corp.’s Diabetes Health business for $235 million in cash and Strive Medical in its entirety, for a combined approximate $360 million in cash, subject to working-capital adjustments.
• Diabetes Health serves more than 225,000 patients annually on a centralised mail-order model, while Strive Medical serves more than 20,000 patients annually in urology, wound care, ostomy and incontinence supplies.
• Both transactions are expected to close subject to customary conditions and regulatory approvals, and are expected to be accretive to Cardinal Health, Inc.’s non-GAAP earnings per share in the first 12 months after close.
• The Diabetes Health price sits against a business whose FY2025 adjusted EBITDA collapsed 56.9 percent year on year to $26.1 million on net revenue of $592.4 million, following a $128 million non-cash goodwill impairment.
• The acquisition thesis for Cardinal Health, Inc. rests on turnaround execution using its ADS platform, manufacturer relationships and the ContinuCare Pathway construct to reverse the payor-mix and channel-shift headwinds that hurt Diabetes Health in 2025.
• Strive Medical strengthens the urology adjacency alongside The Specialty Alliance’s acquisition of Solaris Health, giving Cardinal Health, Inc. both a physician-services layer and a direct-to-patient supplies layer in that therapeutic area.
• For AdaptHealth Corp., the sale accelerates a deleveraging and portfolio-simplification pivot toward Sleep Health, Respiratory Health and Wellness at Home, following the April 2026 refinancing and the announced redemption of the senior notes due 2028.
• Per-patient economics implied by today’s deal are materially lower than the November 2024 Advanced Diabetes Supply Group acquisition, indicating that Cardinal Health, Inc. is now consolidating diabetes distribution at improving unit valuations.
• Cardinal Health, Inc. shares near $237 sit close to a 52-week high, supported by rising price targets at TD Cowen and Bank of America Securities, with fourth-quarter and full-year fiscal 2026 results due on 11 August 2026.
• AdaptHealth Corp. shares near $10.59 remain well below sell-side price targets in the $14 to $15 range, with the deleveraging path and the next quarterly report likely to be the more direct catalysts for re-rating.